Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (11-20 of 326) with videos related to

Pageof 33
Sort By:
Oncology (Williston Park, N.Y.)|February 17, 2015
Optimal treatment selection for patients with metastatic melanomaRyan J Sullivan
Expert Opinion on Therapeutic Targets|November 4, 2010
New drug targets in Kaposi sarcomaRyan J Sullivan, Liron Pantanowitz
American Journal of Clinical Dermatology|November 1, 2015
The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted TherapyHugo Akabane, Ryan J Sullivan
Med (New York, N.Y.)|May 9, 2026
Beyond empiric checkpoint escalation: Insights from KEYVIBE-010Andrew Knight, Ryan J Sullivan
Journal of Cutaneous Pathology|May 21, 2010
Cytokine therapy in melanomaRyan J Sullivan, Michael B Atkins
Melanoma Management|September 8, 2018
<i>NRAS</i> mutant melanoma: an overview for the clinician for melanoma managementRussell W Jenkins, Ryan J Sullivan
Expert Review of Anticancer Therapy|May 19, 2009
Molecular-targeted therapy in malignant melanomaRyan J Sullivan, Michael B Atkins
Journal of Skin Cancer|December 17, 2011
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceRyan J Sullivan, Keith T Flaherty
Expert Review of Clinical Pharmacology|December 5, 2014
Dabrafenib in combination with trametinib for the treatment of metastatic melanomaMark M Awad, Ryan J Sullivan
American Journal of Clinical Dermatology|February 7, 2020
When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?Lauren B Banks, Ryan J Sullivan
Pageof 33

Showing results (11-20 of 326) with videos related to

Sort By:
Pageof 33
Oncology (Williston Park, N.Y.)|February 17, 2015
Optimal treatment selection for patients with metastatic melanomaRyan J Sullivan
Expert Opinion on Therapeutic Targets|November 4, 2010
New drug targets in Kaposi sarcomaRyan J Sullivan, Liron Pantanowitz
American Journal of Clinical Dermatology|November 1, 2015
The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted TherapyHugo Akabane, Ryan J Sullivan
Med (New York, N.Y.)|May 9, 2026
Beyond empiric checkpoint escalation: Insights from KEYVIBE-010Andrew Knight, Ryan J Sullivan
Journal of Cutaneous Pathology|May 21, 2010
Cytokine therapy in melanomaRyan J Sullivan, Michael B Atkins
Melanoma Management|September 8, 2018
<i>NRAS</i> mutant melanoma: an overview for the clinician for melanoma managementRussell W Jenkins, Ryan J Sullivan
Expert Review of Anticancer Therapy|May 19, 2009
Molecular-targeted therapy in malignant melanomaRyan J Sullivan, Michael B Atkins
Journal of Skin Cancer|December 17, 2011
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and ResistanceRyan J Sullivan, Keith T Flaherty
Expert Review of Clinical Pharmacology|December 5, 2014
Dabrafenib in combination with trametinib for the treatment of metastatic melanomaMark M Awad, Ryan J Sullivan
American Journal of Clinical Dermatology|February 7, 2020
When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?Lauren B Banks, Ryan J Sullivan
Pageof 33